1.
Chem Commun (Camb)
; 56(73): 10706-10709, 2020 Sep 15.
Article
in English
| MEDLINE
| ID: mdl-32789350
ABSTRACT
Resistance to the platinum-based chemotherapy drug, cisplatin, is a significant setback in ovarian cancer. We engineered fatty acid-like Pt(iv) prodrugs that harness the fatty acid transporter CD36 to facilitate their entry to ovarian cancer cells. We show that these novel constructs effectively kill cisplatin-resistant ovarian cancer cells.